Whereas, metformin and DCH treatment significantly decreased the body weight (p < 0.01, respectively, Figure 1A), liver index (p < 0.05, respectively, Figure 1B), and serum levels of TG, TC, AST, and ALT (p < 0.01, respectively, Table 2) compared to the NAFLD model rats. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.